Clinical trial · Observational
Evaluation of Effectiveness of CyberKnife Stereotactic Radiosurgery for Spinal Tumors
Functional Magnetic Resonance Imaging Combined With Radiomics for Evaluation of Effectiveness of CyberKnife Stereotactic Radiosurgery for Spinal Tumors
NCT04192383CI-TRIAL-00052472unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to explore the reliability of the combination of functional magnetic resonance imaging and radiomics for evaluation of the therapeutic efficacy of CyberKnife stereotactic radiosurgery for spinal tumors. Accurate imaging assessment can help clinicians plan personalized therapeutic schedules for patients with spinal tumors .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Spinal Neoplasms | Spinal Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cyberknife stereotactic radiosurgery | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cyberknife
- interventionNames
- Radiation: Cyberknife stereotactic radiosurgery
Primary outcomes (1)
- measure
- Overall survival(OS)
- timeFrame
- From the start of randomization to the date of death of the patient or the end of the study (at 60 months).
- description
- The time from the start of treatment to the date of death or last follow-up
Secondary outcomes (3)
- measure
- Progression-free survival(PFS)
- timeFrame
- From the start of randomization to the first evidence of tumor progression or death of the patient or the end of the study (at 60 months), whichever occurs first.
- description
- The time from the start of treatment to the date of diagnosis of tumor progression or death. Tumor progression is defined as increase in lesion volume on MRI compared to baseline, or identification of new metastasis on imaging or histological examination.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion criteria: * Biopsy-proven spinal or paraspinal metastases; * MRI and DCE-MRI examination performed before and at 3 months after CyberKnife treatment. Exclusion criteria: * Area of the lesion surgically removed before enrollment; * Prior percutaneous vertebroplasty or kyphoplasty or radiation therapy of the target lesion; * Chemotherapy within a month; * Unable to cooperate with-or refusal of-CT, conventional MRI, or DCE-MRI examination; * Lost to follow-up; * Poor image quality that cannot be analyzed.
References
Publications (0)
Data not yet available
No reference posted for this study.